2012年3月28日水曜日

NEJM Audio Summary - March 22, 2012

Excerpted Script
5:47| "A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke" by Mark Parsons, from the University of Newcastle, Australia.
This phase 2B trial, using CT perfusion and angiographic imaging to select patients for thrombolytic treatment of acute ischemic stroke, compared the standard dose of alteplase with two different doses of tenecteplase. The three treatment groups each comprised 25 patients. The mean National Institute of Health Stroke Scale score at baseline for all patients was 14.4, and the time to treatment was 2.9. Together, the two tenecteplase groups had greater reperfusion and clinical improvement at 24 hours than the alteplase group. There were no significant between-group differences in intracranial bleeding or other serious adverse events. The higher dose of tenecteplase (0.25 mg per kilogram) was superior to the lower dose and to alteplase for all efficacy outcomes, including absence of serious disability at 90 days (in 72% of patients, vs. 40% with alteplase. Tenecteplase was associated with significantly better reperfusion and clinical outcomes than alteplase in patients with stroke who were selected on the basis of CT perfusion imaging. 
詳細は、下畑享良先生のブログ"Neurology 興味を持った「神経内科」論文"の記事「脳梗塞に対する血栓溶解薬テネクテプラーゼはアルテプラーゼより優れているようだ」を参照。

0 件のコメント:

コメントを投稿